Verastem, Inc. Stock News

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in the following upcoming investor conferences: 2024 Truist Securities BioPharma Symposium on November 7, 2024 Guggenheim Healthcare Innovation Conference; fireside chat on Wednesday, Novem...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced updated data from the Phase 2 RAMP 201 (ENGOTov60/GOG3052) clinical trial evaluating the combination of avutometinib, an oral RAF/MEK clamp, and defactinib, an oral, selective FAK inhibitor, in patients with recurrent low-grade ser...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced further details for its late-breaking presentation of mature data from the ongoing Phase 2 RAMP 201 (ENGOT-ov60/GOG-3052) clinical trial to be presented as an oral presentation at a plenary session at the International Gynecologic ...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 109,000 shares of its common stock to nine new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employees' acceptance of em...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18 at 3:40 pm EDT. A live webcast of the fireside chat can be accessed under “Events & Presentatio...

Verastem's Avutometinib and Defactinib combination therapy targets recurrent LGSOC and is expected to complete its rolling NDA by 2H2024. The company has a diverse pipeline, exploring treatments for metastatic pancreatic cancer and mKRAS G12C non-small cell lung cancer (NSCLC). Interim results for Avutometinib + Defactinib show a 45% ORR overall and 60% ORR for KRAS-mutant patients, with tumor ...

BOSTON & HOUSTON, Texas--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, and the STAAR Ovarian Cancer Foundation today announced the first Low-Grade Serous Ovarian Cancer Awareness Day or “LGSOC Awareness Day” on September 9, 2024. September is Ovarian Cancer Awareness Month and LGSOC is a rare ovarian...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to avutometinib, a RAF/MEK clamp, in combination with defactinib, a selective FAK inhibitor, for the treatment of pancreatic cancer. “At the ASCO 2024 A...